iNovacia adds 20,000 new compounds to screening collection
This article was originally published in Scrip
Executive Summary
iNovacia, the drug discovery service provider and subsidiary of Sweden's Kancera, has added more than 20,000 novel compounds to the existing 280,000 compounds in its small-molecule screening collection.